Limits...
Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.

Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, Shih IeM - Int J Mol Sci (2010)

Bottom Line: With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs.There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival.In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; E-Mails: daichimaeda@gmail.com (D.M.); mfukayama-tky@umin.net (M.F.).

ABSTRACT
Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In this study, we determined the significance of loss of ARID1A immunoreactivity with respect to several clinicopathological features in a total of 149 OCCCs. First, we demonstrated that ARID1A immunohistochemistry showed concordance with the mutational status in 91% of cases with 100% sensitivity and 66% specificity. Specifically, among 12 OCCC cases for which ARIDA mutational status was known, ARIDIA immunoreactivity was undetectable in all 9 cases harboring ARID1A mutations and was undetectable in one of 3 cases with wild-type ARID1A. With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs. There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival. In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier analysis demonstrates lack of significance between ARID1A immunoreactivity and overall survival in multivariate analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3100854&req=5

f2-ijms-11-05120: Kaplan-Meier analysis demonstrates lack of significance between ARID1A immunoreactivity and overall survival in multivariate analysis.

Mentions: Next, we assessed the potential effects of loss of ARID1A expression on clinicopathological features of OCCCs by correlating ARID1A expression with several clinical and pathological characteristics of OCCC (Table 4). We found that there was no significant association of ARID1A expression and age at disease presentation, clinical stage, metastasis in lymph node, or histological features (p > 0.05). ARID1A immunoreactivity was not significantly correlated with adenofibromatous versus cystic OCCC (p = 0.266), although there was a trend toward the association of loss of ARID1A expression with cystic lesions among OCCCs with a substantial adenofibromatous component (≥10%) (Table 4). Similarly, there was no significant difference between ARID1A expression and structural patterns including papillary, tubulocystic, and solid features (p = 0.957) or between ARID1A immunoreactivity and nuclear grade (p = 0.232). Kaplan-Meier analyses were performed to determine if there was a correlation between ARID1A expression and clinical outcome. No significant difference in survival was found between ARID1A positive and negative cases (P = 0.97) (Figure 2).


Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.

Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T, Taketani Y, Shih IeM - Int J Mol Sci (2010)

Kaplan-Meier analysis demonstrates lack of significance between ARID1A immunoreactivity and overall survival in multivariate analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3100854&req=5

f2-ijms-11-05120: Kaplan-Meier analysis demonstrates lack of significance between ARID1A immunoreactivity and overall survival in multivariate analysis.
Mentions: Next, we assessed the potential effects of loss of ARID1A expression on clinicopathological features of OCCCs by correlating ARID1A expression with several clinical and pathological characteristics of OCCC (Table 4). We found that there was no significant association of ARID1A expression and age at disease presentation, clinical stage, metastasis in lymph node, or histological features (p > 0.05). ARID1A immunoreactivity was not significantly correlated with adenofibromatous versus cystic OCCC (p = 0.266), although there was a trend toward the association of loss of ARID1A expression with cystic lesions among OCCCs with a substantial adenofibromatous component (≥10%) (Table 4). Similarly, there was no significant difference between ARID1A expression and structural patterns including papillary, tubulocystic, and solid features (p = 0.957) or between ARID1A immunoreactivity and nuclear grade (p = 0.232). Kaplan-Meier analyses were performed to determine if there was a correlation between ARID1A expression and clinical outcome. No significant difference in survival was found between ARID1A positive and negative cases (P = 0.97) (Figure 2).

Bottom Line: With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs.There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival.In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; E-Mails: daichimaeda@gmail.com (D.M.); mfukayama-tky@umin.net (M.F.).

ABSTRACT
Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In this study, we determined the significance of loss of ARID1A immunoreactivity with respect to several clinicopathological features in a total of 149 OCCCs. First, we demonstrated that ARID1A immunohistochemistry showed concordance with the mutational status in 91% of cases with 100% sensitivity and 66% specificity. Specifically, among 12 OCCC cases for which ARIDA mutational status was known, ARIDIA immunoreactivity was undetectable in all 9 cases harboring ARID1A mutations and was undetectable in one of 3 cases with wild-type ARID1A. With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs. There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival. In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.

Show MeSH
Related in: MedlinePlus